Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The user is experiencing hair loss despite using dutasteride, minoxidil, and ketoconazole shampoo, and is concerned about continued shedding. Suggestions include checking for nutrient deficiencies, consulting a dermatologist, and considering other potential causes like seborrheic dermatitis or telogen effluvium.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The conversation discusses hair regrowth treatments using finasteride, minoxidil pills, and topical minoxidil, with a focus on the use of a 1.5mm derma roller. Users advise caution with derma rolling, suggesting smaller needle sizes and longer intervals between sessions to avoid skin damage and systemic absorption of minoxidil.

Dutasteride may inhibit new beard growth, but minoxidil can still promote beard growth, albeit slowly. Some users report thicker beards with oral minoxidil despite using dutasteride.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A 26-year-old uses topical minoxidil, oral finasteride, and Nizoral shampoo for hair thinning and is considering microneedling but is unsure about the best approach. Users suggest using a 1.0mm dermaroller once a week, cautioning against overuse due to potential scarring, and some recommend combining microneedling with minoxidil for better absorption.

The user is experiencing hair thinning despite using finasteride and minoxidil with added tretinoin, and is considering switching to dutasteride. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

Celebrities using hair loss treatments like finasteride, minoxidil, and hair transplants is common and helps normalize these practices for the public. Many believe acknowledging this reduces stigma and provides reassurance that these treatments are effective and widely used.

The user has been using dutasteride, minoxidil, and RU58841 for a year to stabilize hair loss and is considering a hair transplant. They are taking 5mg of oral minoxidil daily and are unsure of its effectiveness but have noticed more hair than a year ago.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The user started finasteride in 2017, added oral minoxidil in 2024, and began microneedling in 2025, achieving significant hair regrowth without side effects. They recommend using all three treatments together for the best results.

A new hair loss treatment shows promise in mice but is unproven in humans. Effective treatments include finasteride and minoxidil.

Managing seborrheic dermatitis using ketoconazole shampoo, Nizoral, and oils like MCT and coconut oil. The user considers shaving their head and consulting a dermatologist.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Hair follicles often go dormant rather than die, and treatments like minoxidil can help revive them. Scalp health and stimulation, such as massages and using products like sulphur soap, are also important for hair regrowth.

The conversation discusses various supplements and vitamins like Vitamin D3, K2, Biotin, Iron, Zinc, and B Vitamins for improving hair health. It also mentions a combination of Tocotrienols, Pycnogenol, Saw Palmetto, Pumpkin Seed Oil, Stinging Nettle, and Myricetin for stabilizing hair, with Saw Palmetto, Pygeum, and Stinging Nettle noted for thickening hair despite side effects.

Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

Creatine may cause hair loss in some individuals, especially those on finasteride, despite no scientific link. Personal experiences suggest individual sensitivity to DHT could be a factor.

A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Hair provides protection against head trauma, reduces skin cancer risk, helps remove heavy metals, and aids in wound healing. The conversation emphasizes the health benefits of maintaining head hair beyond cosmetic reasons.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.